Quiver Bioscience

Quiver Bioscience is a private, pre-clinical stage biotech leveraging a proprietary, integrated platform of human disease models, scalable neural measurement technology, and AI to tackle the high failure rates in neurological drug development. The company has built a pipeline of wholly-owned antisense oligonucleotide (ASO) programs targeting genetically-validated pathways in chronic pain and developmental epileptic encephalopathies, and has secured strategic research collaborations with pharmaceutical partners. Positioned at the intersection of genetics, scalable biology, and computational power, Quiver aims to become a premier partner in translating target discovery into clinical candidates for CNS disorders.

Integrated platform combining: 1) Patient-derived stem-cell and ex vivo tissue slice models for human-relevant disease phenotyping; 2) Proprietary all-optical electrophysiology for high-throughput (>10,000x), gold-standard measurement of neuron function (action potentials); 3) AI/ML models to mine high-dimensional data for disease phenotyping, drug efficacy assessment, target-drug matching, and toxicity prediction.

Quiver competes with other AI-driven biotechs (e.g., Recursion, Exscientia) applying computational methods to drug discovery, and with neurology-focused platform companies using stem cell models (e.g., Cerevel, though later-stage). Its specific integration of high-throughput electrophysiology is a key differentiator. In its target areas (e.g., Nav1.7/1.8 for pain), it faces competition from both large pharma and biotechs like Vertex.